OBJECTIVE: Obesity is a costly, deadly public health problem for which new treatments are needed. Individual differences in meal pattern have been proposed to have a role in obesity risk. The present study tested the hypothesis that (i) the microstructure of chronic high-fat diet intake differs between genetically selected diet-induced obesity (DIO) and diet-resistant (DR) rats, and (ii) central administration of urocortin 2 (Ucn 2), a corticotropin-releasing factor type 2 agonist, decreases high-fat diet intake not only in lean DR rats, but also in obese DIO rats. DESIGN: Male, selectively bred DIO and DR rats (n ¼ 10/genotype) were chronically fed a high-fat diet. Food and water intake as well as ingestion microstructure were then compared under baseline conditions and following third intracerebroventricular injection of Ucn 2 (0, 0.1, 0.3, 1, 3 mg). RESULTS: Irrespective of genotype, Ucn 2 reduced nocturnal food intake with a minimum effective dose of 0.3 mg, suppressing high-fat diet intake by B40% at the 3 mg dose. Ucn 2 also made rats of both genotypes eat smaller and briefer meals, including at doses that did not reduce drinking. Obese DIO rats ate fewer but larger meals than DR rats, which they ate more quickly and consumed with two-third less water. CONCLUSIONS: Unlike leptin and insulin, Ucn 2 retains its full central anorectic efficacy to reduce high-fat diet intake even in obese, genetically prone DIO rats, which otherwise show a 'gorging' meal pattern. These results open new opportunities of investigation toward treating some forms of DIO.
INTRODUCTION
Obesity is a major public health problem that increases morbidity, mortality and economic burdens.
1,2 Some individuals may be susceptible to becoming obese when exposed to palatable, calorically dense food [3] [4] [5] because of an inherited resistance to the negative feedback influence of neuropeptides and peripheral hormones 6 on energy metabolism and appetite. [7] [8] [9] [10] [11] Accordingly, Levin and colleagues selectively bred rats for differential weight gain responses to a high-fat/high-energy diet. The resulting dietinduced obesity (DIO)-prone and diet-resistant (DR) rat lines model the polygenic individual differences in human vulnerability to DIO. [12] [13] [14] When fed a high-fat diet, DIO rats become fatter than DR rats, which do not gain excess weight or body fat; [12] [13] [14] in contrast, young adult DIO rats remain lean when fed low-fat food, per a gene-environment interaction.
14, 15 The effects of high-fat diet on body weight and metabolism in genetically selected DIO rats are well studied, 4, 12, 13, 16 but it remains unclear whether DIO rats eat differently than do DR rats. The microstructure of intake 15, 17 can provide key insights into the controls of feeding 18, 19 and has been linked to body composition; in humans, increased meal size and decreased meal frequency are putative risk factors for obesity. [7] [8] [9] [10] [11] Still lean, but obesity-prone DIO rats show a snacking-like microstructure pattern when fed a regular chow diet, consuming more, but smaller, meals than chow-fed DR rats. 15 It is unknown, however, whether these two genetic animal lines eat differently when chronically fed a high-fat diet, a key question given that the lines' weight and adiposity differ as young adults, only when challenged by high-fat diet. The first aim of the present study was to test the hypothesis that the microstructure of food intake differs between high-fat diet-fed DIO and DR rats.
Relative to lean individuals, obese individuals are resistant to the appetite suppressant and weight-loss-promoting properties of several anorexigens, including leptin and central insulin. [20] [21] [22] [23] [24] [25] [26] Resistance states perpetuate obesity; potential weight-reducing pharmacotherapies must engage substrates downstream of or parallel to the signaling resistance. The urocortin (Ucn)/ corticotropin-releasing factor 2 receptor (CRF 2 ) system is a potential therapeutic target for overeating and obesity.
hypothalamic nuclei and the nucleus of the solitary tract. 36 Central administration of Ucn 2 and Ucn 3, endogenous CRF 2 agonists, suppress food intake at doses that do not elicit malaise-or anxiety-like behavior. 15, [31] [32] [33] 37, 38 Moreover, CRF 2 knock-out mice eat larger meals, 29 with increased nocturnal intake of sweet chow 29 and high-fat food 30 vs wild-type mice. 16, 39, 40 Ucn 2 retains its maximal anorectic efficacy, in chow-fed, lean DIO rats, 15 unlike leptin and insulin. 16, 38, 39 The anorectic effectiveness of CRF 2 agonists in high-fat diet-fed obese DIO rats is unknown. The second aim of the present study was therefore to test the hypothesis and microstructure mechanism by which central administration of Ucn 2 decreases intake of high-fat food similarly in obese genetically selected DIO as in lean DR rats.
MATERIALS AND METHODS
Please see Supplementary Material for additional details.
Subjects
Male DIO (n ¼ 10) and DR (n ¼ 10) rats, descendants of the original DIO and DR rat colonies (from Levin et al. 13 
Drugs
Rat Ucn 2 and angiotensin II, generously provided by Dr Jean Rivier (The Salk Institute, La Jolla, CA, USA), were synthesized as previously described. 41, 42 Ucn 2 and angiotensin II were dissolved in 0.5 Â phosphate-buffered saline and 1 Â phosphate-buffered saline (pH ¼ 7.4), respectively.
Intra-cranial surgery and injection procedures
Because type 2 Ucns can suppress food intake via hypothalamic sites of action, 15, 31 stainless steel cannulae were stereotaxically implanted in isoflurane-anesthesized rats to target the third ventricle (3v; interaural flat-skull; anterior/posterior À 0.8 mm from bregma; dorsal/ventral: À 3.5 mm from skull). 15, 43 For testing, drug solutions or vehicle (2 ml) were injected over 90 s with a Hamilton microsyringe (Reno, NV, USA) linked by PE 20 tubing to a 31-G injector projecting 3 mm beyond the guide cannula. Injectors were left in place for 1 min. Placement was functionally verified post study as a positive dipsogenic response (45 ml water intake per 30 min) to 3v angiotensin II (100 ng per 2 ml).
Microstructural analysis of ingestion
Apparatus. To study the microstructure of ingestion, rats were individually housed in previously described Plexiglass test cages. 17 Bioserv, Frenchtown, NJ, USA) was a 45-mg precision-pelleted variation of the high-fat diet that rats consumed in their home cages. Water delivery (0.1 ml) into a reservoir was governed by a response-contingent solenoid activated by nose-poke interruption. Post-reinforcement timeout intervals (3.25 and 1 s for food and water, respectively) prevented duplicate reinforcement. 15 
Study design
Beginning from 50 days of age, DR and DIO rats were provided only a high-fat diet in their home cages (D12266B) unless otherwise specified.
Rats resided in and learned how to obtain food and water in the microstructure enclosures beginning from 110 to 120 days of age. After establishing stable daily food and water intake (12-13 sessions), rats remained in their home cages for chronic diet exposure. At 218 days of age, rats were implanted with the 3v guide cannula and allowed to recover for one week. Microstructure housing resumed at 226 days of age. After reattainment of stable food intake (12-13 sessions), rats were provided highfat diet in the enclosure. After high-fat diet intake stabilized (o15% food intake variation across 3 consecutive days), spontaneous baseline high-fat diet intake and meal microstructure of DIO vs DR high-fat rats were measured at 241 and 242 days of age. To determine the effects of acute central Ucn 2 administration on high-fat diet intake, rats then received 3v doses of 0, 0.1, 0.3, 1 or 3 mg 10 min before testing. Based on previous studies, 15, 32, 33 these infusions were given using a within-subject Latin square design with one to two intervening treatment-free days beginning from 244 days of age. Food and water intake were monitored as nose-poke responses for 23.5 h.
Meal pattern analysis. Microstructure analysis used a meal definition that recognizes the existence of prandial drinking within meals 45 and was performed as previously described. 15 Meals were defined to contain at least 0.09 g of food (two pellets). Parameters included meal frequency; the average size, duration and ingestion rate of meals; and the average intermeal interval.
Within-meal microstructure analysis. To identify differences between highfat diet-fed DIO vs DR rats in the rate and regularity of sustained eating within meals, analysis of the log-normal(ln)-transformed duration of consecutive (uninterrupted by drinking) within-meal interfeeding intervals (IFIs) was performed. 15, 17 The mean, standard deviation, kurtosis, skewness and histogram entropy of the ln-transformed duration of each subject's consecutive IFIs was individually determined and averaged across subjects.
Fat pad and body composition analysis
Two days after completing the Ucn 2 study, animals were euthanized (262 days of age). Frozen carcasses were shipped to the University of Alabama at Birmingham for fat pad measurement and chemical analysis of eviscerated body composition. 46 
Statistical analysis
To analyze the time course of ingestion, analyses of variance (ANOVAs) were performed on incremental (1-hr bins) food intake, averaged from the two baseline days. Genotype was a between-subjects factor and time a within-subject factor. Student's t-tests identified genotype differences in spontaneous meal microstructure. To compare fat measures, analysis of covariance (ANCOVA) was used, 47 with the fat measure as the dependent measure, genotype as the between-subjects factor and non-fat mass as a covariate. To allow comparison with other work, fat measures also were compared as a percentage of body weight by Student's t-test.
To assess Ucn 2 anorexia, a three-way mixed ANOVA was performed on incremental (1-hr bins) food intake. Dose and time were withinsubject factors, and genotype was a between-subjects factor. Meal microstructure measures were analyzed by two-way (dose and genotype) ANOVAs. Linear contrasts determined whether Ucn 2 exerted a log-linear, dose-dependent effect. Intermeal interval durations were ln-transformed. 15, 45, 48 To interpret main effects, post hoc pairwise comparisons were performed within the general linear model. The software packages used were Systat 11.0 (SPSS, Chicago, IL, USA), Excel 2003 (Microsoft, Redmond, WA, USA), SigmaPlot 11.0 (Systat Software, Inc., Point Richmond, CA, USA) and InStat 3.0 (GraphPad, San Diego, CA, USA).
RESULTS

Spontaneous food intake in high-fat diet-fed DR and DIO rats
Time course of ingestion. Time course analysis of nocturnal food intake revealed no genotype (F(1,18) ¼ 0.04, P ¼ 0.84) or hour*-genotype effects (F (11, 198 ) ¼ 1.42, P ¼ 0.17; Figure 1a ). While no genotype effect was seen on diurnal intake (F(1,18) ¼ 0.39, P ¼ 0.56), an hour*genotype interaction (F (11, 198 ) ¼ 3.26, Po0.001), reflected that DIO rats ate less than DR rats during the first hour of the light cycle (M±s.e.m. 2.2±0.6 g vs 0.3±0.2 g, t(18) ¼ 3.1, Po0.01), but then progressively compensated and attained control levels of total intake by the end of the light cycle ( Figure 1a) . Thus, consistent with previous findings, 49 DIO rats ultimately ate as much high-fat diet as DR rats across each phase of the day (Supplementary Table 1) .
DR and DIO rats also were similar in their duration of nocturnal feeding (Supplementary Table 1 ). In contrast, DIO rats drank less water than DR rats in both quantity (B1/3; t(18) ¼ 4.6, Po0.001) and duration (B1/2; t(18) ¼ 3.3, Po0.01) during the dark cycle. During the light cycle, despite eating the same amount, DIO rats spent less time eating (t(18) ¼ 2.3, Po0.05) and drank less water (t(18) ¼ 3.5, Po0.01) than DR rats (Supplementary Table 1 ).
Meal pattern. Although DR and DIO rats consumed the same amount of high-fat diet across 24 h, their microstructures of food intake profoundly differed. DIO rats ate B1.2-1.4 g more food per meal (dark cycle: Figure 1c ) and ate faster within meals (dark: t(18) ¼ 2.9, Po0.01; light: t(18) ¼ 2.5, Po0.05, Figure 1d ), yielding meals of similar duration (Dark: Figure 1e ). DIO rats ate fewer meals than DR rats (dark: t(18) ¼ 3.0, Po0.01; light: t(18) ¼ 2.9, Po0.01, Figure 1f ), with B40 min longer nocturnal post-meal intervals (dark: t(18) ¼ 2.9, Po0.01; light: t(18) ¼ 0.3, n.s., Figure 1g ).
Rate and regularity of eating within meals. Within meals, DIO rats had B1.2-1.5 s faster pellet-to-pellet intake than did DR rats (t(18) ¼ 3.1, Po0.01, Table 1 ). In Figure 1b , the faster mean rate of eating by DIO rats is seen as a disproportionate left-shift toward briefer IFIs, resulting in a significantly more positive skew (t(18) ¼ 2.3, Po0.05) and decreased kurtosis vs DR rats; (t(18) ¼ 2.7, Po0.02). The genotypes did not differ significantly in their regularity of eating, as measured by the standard deviation or histogram entropy of IFIs (standard deviation: t(18) ¼ 1.8, n.s.; entropy: t(18) ¼ 2.0, n.s.).
Body weight, fat pad and body composition analysis Table 2 shows the body weight progression of DR and DIO rats, their rate of weight gain, daily energy intake and feed efficiency during the first month of high-fat diet feeding, and their terminal adiposity. Similar to previous findings, 14 DIO rats ate more, gained more weight and were more feed efficient vs DR rats during the first 8 days of high-fat access. During the subsequent B3 weeks, daily food intake no longer differed significantly between the two genotypes, yet DIO rats still gained weight faster than DR rats, reflecting increased feed efficiency. At study end, DIO rats had heavier fat pads and more total carcass fat (Supplementary Table 3 ). ANCOVA analyses controlling for non-fat mass indicated that, other than for gonadal fat (P ¼ 0.58), the relative fat pad and whole carcass fat masses of high-fat diet-fed DIO rats were disproportionately increased vs DR rats (see Table 2 for adjusted means, covarying for non-fat mass). The sometimes problematic, 47 but popular, method of expressing fat mass as a % of body weight (Table 2 ) also indicated greater relative adiposity. Adiposity values of DR and DIO rats were consistent with lean and obese states, 13, 15 respectively. Ucn 2 anorexia in high-fat diet-fed DR and DIO rats Effects of Ucn 2 on high-fat food and water intake: time course. Figure 2a shows that 3v injection of Ucn 2 reduced nocturnal food intake of high-fat diet-fed DR and DIO rats (dose: F(4,72) ¼ 11.12, Po0.001). Although visual inspection of Figure 2a might suggest that Ucn 2 tended to reduce food intake more potently in DR rats compared with DIO rats, statistical analyses consistently indicated a main effect of Ucn 2 across genotypes, with no significant (or even trends for) dose Â genotype interactions. Ucn 2 retained its full central anorectic efficacy in obese DIO rats; the highest dose injected (3 mg) induced similar anorexia in both genotypes (% reduction after 12 h: M ± s.e.m., DR 38.5%±7.0%, DIO 41.3%±10.4%). Cumulative anorexia was greatest at the end of the dark cycle (Figure 2a, inset) , so microstructure analyses were performed across this period. Cumulative anorexia persisted through the light cycle (not shown), with no compensation or rebound.
As Table 3 shows, Ucn 2 reduced the quantity (dose: F(4,72) ¼ 10.46, Po0.001) and duration (dose: F(4,72) ¼ 7.26, Po0.001) of prandial nocturnal food intake irrespective of Abbreviations: DIO, diet-induced obesity; DR, diet resistant. Body weight, body weight gain, food intake, feed efficiency and adiposity in high-fat diet-fed DR and DIO rats (n ¼ 10 rats per genotype). Feed efficiency was calculated as mg body weight gained per kcal energy intake. Weights (g) of fat pad and whole carcass fat (g) reflect the adjusted least squares means, controlling for non-fat mass. Percent (%) fat pad and whole carcass percent (%) fat values reflect the fat masses expressed as a percent of body weight. Raw fat masses, uncorrected for lean body mass, are shown in Supplementary (F(1,18) ¼ 0.05, n.s.). But, Ucn 2-treated DIO rats ate meals that no longer differed from those normally taken by obesity-resistant DR rats under vehicle-treated conditions (DIO 1 mg and 3 mg ¼ 2.8 ± 0.6 and 3.3 ± 0.5 g vs DR-vehicle 3.0 ± 0.3 g, P40.57).
In contrast, Ucn 2 did not alter the amount or duration of water intake within a meal (dose: Fs(4,72)o1. 50 Table 2) .
As shown in Table 4 , Ucn 2 treatment (1 mg) increased the mean duration of inter-pellet intervals in within-meal microstructure analysis (dose: F(4,72) ¼ 4.09, Po0.006). Moreover, Ucn 2 infusion (1 mg) also reduced the categorical regularity of pellet-to-pellet responding as revealed by increased histogram entropy (F(4,72) ¼ 3.82, Po0.01). In contrast, Ucn 2 did not reliably alter the standard deviation of inter-pellet intervals or the skewness or kurtosis of their distribution (Fs(4,72)o1.96, n.s.). No effects of Ucn 2 on within-meal microstructure differed reliably by genotype (dose*genotype: Fs(4,72)o1.80, n.s.). Genotype main effects again indicated that DIO rats had disproportionately faster pellet-topellet intake, reflected in a briefer mean IFI (F(1,18) (Fs(1,18) o1.18, n.s.).
DISCUSSION
The major findings of the present study were as follows: (1) 3v administration of the CRF 2 agonist Ucn 2 retained anorectic activity in obese, high-fat diet-fed DIO rats. The peptide potently reduced nocturnal food intake in both genotypes at a MED of 0.3 mg, with similar maximal efficacy between genotypes; (2) 3v Ucn 2 reduced high-fat diet intake by making rats of both genotypes eat smaller meals that they ate more slowly; and (3) obese, high-fat diet-fed DIO rats, showed a 'gorging pattern' of food intake, characterized by few, but very large and more quickly eaten, meals and comparatively little water intake.
Ucn 2 retains central anorectic activity in obese high-fat diet-fed DIO rats Ucn 2 infused into the 3v dose-dependently decreased high-fat diet intake not only in lean DIO rats, but also in obese DIO rats. Irrespective of genotype, the peptide reduced nocturnal food intake at a MED of 0.3 mg (B64 pmol). Although we cannot rule out that a larger study might have revealed subtle differences in dose sensitivity between the genotypes, the maximal efficacy of Ucn 2 was unimpeded in the DIO line, with similar maximal suppression of food intake (B40%) seen at the 3 mg dose. Consistent with previous observations in chow-fed rodents, 15, 32 intraventricular Ucn 2 administration elicited a slightly delayed (B2 h), but prolonged, anorectic action. Ucn 2 did not change the timing of when meals were taken, but rather reduced the gorgelike nature of high-fat meals, making rats eat smaller meals that were eaten more slowly. Because Ucn 2 treatment similarly influenced both genotypes, the overall meal pattern of DIO rats still differed from that of DR rats following Ucn 2 treatment. But, Ucn 2 treatment normalized the meal size of DIO rats to that normally eaten by obesity-resistant DR rats.
The mechanism by which 3v Ucn 2 reduced food intake was not explored in the present study, but accumulated results indicate behaviorally specific actions. Ucn 2 hypodipsia 15, 32 was dissociable from anorexia because some Ucn 2 doses that reduced high-fat diet intake in DIO rats (for example, 0.3, 1 mg) did not reduce their concurrent water intake. Similarly, as in previous studies, 15, 36 reductions in drinking rate were not seen. Furthermore, the present intraventricular Ucn 2 doses do not promote anxiety-like behavior or the formation of malaise-like behavior, such as pica or a conditioned taste aversion in outbred rats. 36 Local administration of CRF 2 agonist into the CRF 2 -rich ventromedial hypothalamus, a key brain site that controls food intake and energy metabolism, 50,51 also reduces food intake. 31, 34 Thus, the present results may reflect actions of 3v Ucn 2 at ventromedial hypothalamus CRF 2 receptors, but we cannot exclude roles for other brain sites at which Ucns can reduce food intake and/or slow gastric emptying, 38, 52 including the paraventricular nucleus of the hypothalamus, 31 the lateral septum, 53 or the dorsal vagal complex. 31, 53, 54 Our results further implicate Ucns as promising pharmacological tools to treat obesity or overeating, putatively via CRF 2 activation. 36 For example, Ucn 1 administration reduced food intake not only in lean, but also in ob/ob obese mice, 55, 56 and Ucn 1 potentiated molecular responses to leptin, providing a potential means of surmounting leptin resistance in obesity. 57 ICV Ucn 2 administration reduced the overeating of palatable cafeteria diet under an intermittent access schedule. 33 Finally, mice deficient in Ucn 3 or ventromedial hypothalamus CRF 2 expression are hyperphagic. 34 Genotype differences in high-fat meal microstructure of DR and DIO rats Meal patterns associate with body composition in humans and may have a causal role in obesity. [7] [8] [9] Consistent with previous findings, DIO rats only transiently overate high-fat diet, with intake levels eventually declining to those of DR rats; yet they continued to gain excess weight and become obese. 49 Microstructure analysis revealed profound differences in how the two genotypes ate, however. Relative to their obesity-resistant counterparts, DIO rats ate B1.2-1.4 g more food per meal and ate more quickly within meals (B1.2-1.5 s faster pellet-to-pellet intake). These gorging-like meals were B40 min longer apart. One interpretation of these findings is that, relative to DR rats, obese DIO rats may show decreased within-meal satiation for high-fat diets, leading to larger meals that sustain an increased post-meal interval. Obese DIO rats also drank B2/3 less water during meals than did lean DR rats. Perhaps the decreased prandial water intake of DIO rats contributes to their decreased within-meal satiation. Accordingly, in humans, drinking water reduces test meal intake and promotes weight loss. 58, 59 Unlike results from the present study with high-fat diet, we previously observed that chow intake in lean DIO rats was characterized by more, but smaller, meals as compared to chowfed DR rats, resembling human 'snacking' behavior. 15, 60 If results from the two studies are combined, high-fat diet induced a gorging-like pattern of food intake in both genotypes. Specifically, high-fat diet doubled the meal size of DR rats (from B9 to B17 kcal) and tripled that of DIO rats (from B7 to B22 kcal). Conversely, meals were taken less frequently (DIO: from B11 to B4 meals; DR: from B8 toB6 meals,) with longer post-meal intervals (DIO: from B59 to B153 min; DR: from B90 to B113 min; Supplementary Table 4) . The results support reports that high-fat diets increase meal size, but decrease meal frequency, as compared with a balanced diet 7, 61, 62 and descriptively suggest that this effect may be especially pronounced in obesity-prone DIO rats.
The gorge-like meal pattern induced by high-fat diet may be more relevant to the development of obesity in the DIO line than the snacking-like pattern previously seen with chow access because DIO rats do not become obese when fed chow diet. Accordingly, eating infrequent, large meals has been hypothesized to promote obesity, perhaps due to effects of this meal pattern on metabolism. [7] [8] [9] [10] [11] In humans, intentionally consuming more frequent, but smaller meals, reduced body weight as compared with consuming the same calories in larger and infrequent meals. 63 Conversely, intentionally decreasing the number of meals facilitates fat mass accumulation. 9 These causal observations are consistent with correlational findings in animal models. 7, 61, 64 Meal patterns in the present study were measured after chronic high-fat diet exposure, which resulted in obesity in DIO rats. The relative contributions of DIO genotype vs obesity to the meal pattern differences are thereby uncertain. Because high-fat diet rapidly increases meal size and decreases meal frequency, 7 we believe that high-fat diet, interacting with genotype, underlies the present meal pattern findings. Future studies that compare the high-fat diet intake patterns of still lean DIO rats vs obese DIO rats can address the contribution of the obese state.
Obese individuals exhibit resistance to many anorectic agents, including leptin, insulin, cholecystokinin and mu-opioid receptor antagonists. [20] [21] [22] [23] [24] [25] [26] [65] [66] [67] [68] [69] [70] Analogously, DIO rats are resistant to leptin and insulin both in a pre-obesity state and after the development of obesity. 16, 39, 40 Unlike other anorexigens, Ucn 2 retains its full central anorectic efficacy to reduce high-fat diet intake even in obese, genetically prone DIO rats. These results open new potential opportunities of investigation toward treating some forms of DIO.
